Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G

被引：2
|
作者：
Sugimoto, Naotoshi
Sakai, Daisuke
Tamura, Takao
Hara, Hiroki
Nishina, Tomohiro
Esaki, Taito
Okuda, Hiroyuki
Denda, Tadamichi
Tsuda, Masahiro
Satoh, Taroh
Makiyama, Akitaka
Yamazaki, Kentaro
Kuramochi, Hidekazu
Hosokawa, Ayumu
Tsuda, Takashi
Taniguchi, Hiroya
Kishimoto, Junji
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Gastrointestinal Oncol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[3] Kinki Univ, Osaka, Japan
[4] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[5] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Fukuoka, Japan
[7] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[8] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan
[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[10] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan
[11] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[12] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi, Chiba, Japan
[13] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan
[14] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
[15] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[16] Kyushu Univ, Fukuoka, Fukuoka, Japan
[17] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[18] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[19] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Jorge Aparicio
    Javier Salvador
    José María Puerto Pica
    Antonio Rueda
    Antonio Lorenzo
    Carlos González de la Puente
    Pablo Borrega
    José Andrés Moreno-Nogueira
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 339 - 345
  • [42] Phase I/II study of irinotecan (CPT-11) combined with 1-leucovorin (I-LV) and 5FU in patients with advanced colorectal cancer
    Komatsu, Y
    Takei, M
    Kato, T
    Miyagishima, T
    Kunieda, Y
    Tateyama, M
    Wakahama, O
    Takeda, H
    Kato, M
    Sugiyama, T
    Asaka, M
    Sakata, Y
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 437 - 437
  • [43] A UGT1A1 genotype-directed phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC)
    Kim, T.
    Sym, S.
    Lee, S.
    Ryu, M.
    Lee, J.
    Chang, H.
    Kim, H.
    Shin, J.
    Kang, Y.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy
    Cunningham, D
    Glimelius, B
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 6 - 12
  • [45] Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    Garufi, C
    Vanni, B
    Aschelter, AM
    Zappalà, AR
    Bria, E
    Nisticò, C
    Sperduti, I
    Cognetti, F
    Terzoli, E
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) : 608 - 616
  • [46] RANDOMIZED PHASE III STUDY OF IRINOTECAN (CPT-11) VERSUS WEEKLY PACLITAXEL (WPTX) FOR ADVANCED GASTRIC CANCER (AGC) REFRACTORY TO COMBINATION CHEMOTHERAPY (CT) OF FLUOROPYRIMIDINE PLUS PLATINUM (FP): WJOG4007 TRIAL
    Machida, N.
    Hironaka, S.
    Shinozaki, K.
    Sato, M.
    Taku, K.
    Watanabe, K.
    Amagai, K.
    Okuno, T.
    Baba, E.
    Goto, M.
    Tsuji, Y.
    Morita, S.
    Okamoto, I.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 7 - 7
  • [47] Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial
    Ueda, Shinya
    Hironaka, Shuichi
    Yasui, Hirofumi
    Nishina, Tomohiro
    Tsuda, Masahiro
    Tsumura, Takehiko
    Sugimoto, Naotoshi
    Shimodaira, Hideki
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Esaki, Taito
    Nagase, Michitaka
    Fujitani, Kazumasa
    Yamaguchi, Kensei
    Ura, Takashi
    Hamamoto, Yasuo
    Morita, Satoshi
    Okamoto, Isamu
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma - a dual-centre phase II study: the MAC-6
    Choi, C. K. K.
    Chan, R. T. T.
    Tung, S. Y.
    Lui, L.
    Siu, S.
    Au, G. K. H.
    Ho, J. W. C.
    Law, W. L.
    CLINICAL ONCOLOGY, 2008, 20 (02) : 168 - 175
  • [49] Alternating hepatic artery chronotherapy with CPT-11 and systemic chronotherapy with 5-FU/FA plus carboplatin for metastatic colorectal cancer confined to the liver: A phase II study
    Shimonov, M
    Hayat, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 297S - 297S
  • [50] Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial
    Souglakos, J
    Pallis, A
    Kakolyris, S
    Mavroudis, D
    Androulakis, N
    Kouroussis, C
    Agelaki, S
    Xenidis, N
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2005, 69 (05) : 384 - 390
12345